A Phase 1/2 Study of MRT-2359 in People with Advanced Lung Cancer and Other Solid Tumors

Full Title

A Phase 1/2, Open-label, Multicenter Study of Oral MRT-2359 in Patients with MYC-driven and Other Selected Solid Tumors Including Lung Cancer and Diffuse Large B-cell Lymphoma

Purpose

In this study, researchers want to find the highest dose of the investigational drug MRT-2359 that can be given safely in people with advanced lung cancer and other solid tumors. MRT-2359 targets a protein that helps cancer cells grow. By attaching to and destroying that protein, MRT-2359 may cause cancer cells to die. It is taken orally (by mouth).

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

• Participants must have advanced non-small cell lung cancer, small cell lung cancer, neuroendocrine cancer, or a solid tumor with elevated activity of the L-MYC or N-MYC proteins.
• At least 3 weeks must pass between the completion of prior anticancer therapies and receipt of MRT-2359.
• Patients must be able to walk and do routine activities for more than half of their normal waking hours.
• This study is for people age 18 and older.

Contact

For more information and to ask about eligibility for this study, please contact the office of Dr. Noura Choudhury at 646-608-3762.